Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Zaffaroni

Showing results (111-120 of 133) with videos related to

Pageof 14
Sort By:
European Journal of Cancer (Oxford, England : 1990)|January 22, 2005
Molecular characterisation of two human cancer cell lines selected in vitro for their chemotherapeutic drug resistance to ET-743S Marchini, E Marrazzo, R Bonomi, et al.
Cancer|December 26, 2001
A novel taxane active against an orthotopically growing human glioma xenograftD Laccabue, M Tortoreto, S Veneroni, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 17, 2009
Renewal of the T-cell compartment in multiple sclerosis patients treated with glatiramer acetateM Chiarini, A Sottini, C Ghidini, et al.
The Journal of Clinical Endocrinology and Metabolism|March 9, 2006
Ghrelin secretion in preterm neonates progressively increases and is refractory to the inhibitory effect of food intakeS Bellone, R Baldelli, G Radetti, et al.
Multiple Sclerosis International|November 22, 2013
Growth hormone and disease severity in early stage of multiple sclerosisM Gironi, C Solaro, C Meazza, et al.
Minerva Pediatrica|September 24, 2013
[What new fathers know, think and do: a survey about fathering's attitudes, beliefs and behaviors in a sample of 570 men just after the birth of their newborn]A Pellai, F Festa, F Cilento, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 12, 2006
Pharmacokinetics and metabolism in mice of IDN 5390 (13-(N-Boc-3-i-butylisoserinoyl)-C-7,8-seco-10-deacetylbaccatin III), a new oral c-seco-taxane derivative with antiangiogenic property effective on paclitaxel-resistant tumorsR Frapolli, E Marangon, M Zaffaroni, et al.
La Pediatria Medica E Chirurgica : Medical and Surgical Pediatrics|March 1, 1997
[Malformations of the midline. A case-control study]A Guala, G Pastore, P Cerruti Mainardi, et al.
Neurology|September 8, 2010
Safety and efficacy of natalizumab in children with multiple sclerosisA Ghezzi, C Pozzilli, L M E Grimaldi, et al.
Neurology|June 17, 1999
Relevance of interleukin 1 receptor antagonist intron 2 polymorphism in Italian MS patientsF L Sciacca, C Ferri, K Vandenbroeck, et al.
Pageof 14

Showing results (111-120 of 133) with videos related to

Sort By:
Pageof 14
European Journal of Cancer (Oxford, England : 1990)|January 22, 2005
Molecular characterisation of two human cancer cell lines selected in vitro for their chemotherapeutic drug resistance to ET-743S Marchini, E Marrazzo, R Bonomi, et al.
Cancer|December 26, 2001
A novel taxane active against an orthotopically growing human glioma xenograftD Laccabue, M Tortoreto, S Veneroni, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 17, 2009
Renewal of the T-cell compartment in multiple sclerosis patients treated with glatiramer acetateM Chiarini, A Sottini, C Ghidini, et al.
The Journal of Clinical Endocrinology and Metabolism|March 9, 2006
Ghrelin secretion in preterm neonates progressively increases and is refractory to the inhibitory effect of food intakeS Bellone, R Baldelli, G Radetti, et al.
Multiple Sclerosis International|November 22, 2013
Growth hormone and disease severity in early stage of multiple sclerosisM Gironi, C Solaro, C Meazza, et al.
Minerva Pediatrica|September 24, 2013
[What new fathers know, think and do: a survey about fathering's attitudes, beliefs and behaviors in a sample of 570 men just after the birth of their newborn]A Pellai, F Festa, F Cilento, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 12, 2006
Pharmacokinetics and metabolism in mice of IDN 5390 (13-(N-Boc-3-i-butylisoserinoyl)-C-7,8-seco-10-deacetylbaccatin III), a new oral c-seco-taxane derivative with antiangiogenic property effective on paclitaxel-resistant tumorsR Frapolli, E Marangon, M Zaffaroni, et al.
La Pediatria Medica E Chirurgica : Medical and Surgical Pediatrics|March 1, 1997
[Malformations of the midline. A case-control study]A Guala, G Pastore, P Cerruti Mainardi, et al.
Neurology|September 8, 2010
Safety and efficacy of natalizumab in children with multiple sclerosisA Ghezzi, C Pozzilli, L M E Grimaldi, et al.
Neurology|June 17, 1999
Relevance of interleukin 1 receptor antagonist intron 2 polymorphism in Italian MS patientsF L Sciacca, C Ferri, K Vandenbroeck, et al.
Pageof 14